Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655759 | 0.97 | — | — | |
| SCHEMBL2657029 | 0.78 | CA2 (0.50) | CA2CHKA | |
| SCHEMBL1832185 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL1832187 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL9079912 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL1475208 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDMMP1MMP2MMP3 | |
| SCHEMBL2655370 | 0.75 | SMN1; SMN2 (0.48) | ALDH1A1MMP1MMP3SMN1; SMN2 | |
| SCHEMBL9019564 | 0.75 | FAAH (0.38) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2655926 | 0.75 | CYP1A2 (0.52) | ALDH1A1HPGD | |
| SCHEMBL9129373 | 0.75 | CYP1A2 (0.52) | ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007019397-A2 | 6-MEMBERED ARYL AND HETEROARYL DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS | GENELABS TECHNOLOGIES, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032488-A1 | 6-Membered aryl and heteroaryl derivatives for treating viruses | GENELABS TECHNOLOGIES, INC. | 2007-02-08 | — | — | US | claimed |
| US-7700638-B2 | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex | N. V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | N.V. ORGANON (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1678144-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX | Akzo Nobel N.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040131-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | AKZO NOBEL N.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
| EP-0515420-B1 | NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES | BOEHRINGER MANNHEIM GMBH (DE) | 1996-06-12 | — | — | EP | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB1, GABRA5, GABRB2 | ALDH1A1 541/4885HPGD 2676/4885MMP1 4878/4885 |
| US-20070032488-A1 | 6-Membered aryl and heteroaryl derivatives for treating viruses | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 1740/4885HPGD 4171/4885MMP1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.